EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Sepsis - Pipeline Review, H1 2017

  • ID: 4091104
  • Report
  • February 2017
  • 278 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Adrenomed AG
  • Batu Biologics Inc
  • Evec Inc
  • Merck & Co Inc
  • Peptinov SAS
  • SetLance srl
  • MORE
Sepsis - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H1 2017, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Sepsis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 10, 6, 1, 60, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 7 molecules, respectively.

Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adrenomed AG
  • Batu Biologics Inc
  • Evec Inc
  • Merck & Co Inc
  • Peptinov SAS
  • SetLance srl
  • MORE
Introduction

Sepsis - Overview

Sepsis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Sepsis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sepsis - Companies Involved in Therapeutics Development

Adrenomed AG

Altor BioScience Corp

Am-Pharma BV

Arch Biopartners Inc.

Aridis Pharmaceuticals LLC

Asahi Kasei Pharma Corp

Astellas Pharma Inc

Batu Biologics Inc

Biomedica Management Corp

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cell2B Advanced Therapeutics SA

Chiome Bioscience Inc

Cilian AG

Dr. Franz Kohler Chemie GmbH

Endacea Inc

Evec Inc

Ferring International Center SA

Huons Co Ltd

Immune Response BioPharma Inc

Immunethep SA

InflaRx GmbH

Inotrem SA

Integrated BioTherapeutics Inc

Lead Discovery Center GmbH

Leading BioSciences Inc

Lixte Biotechnology Holdings Inc

Merck & Co Inc

Navigen Pharmaceuticals Inc

Nohla Therapeutics Inc

Novartis AG

OncoImmune Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Peptinov SAS

ProThera Biologics Inc

Ra Pharmaceuticals Inc

Recce Ltd

Revimmune LLC

Ribomic Inc

SciClone Pharmaceuticals Inc

SetLance srl

Shionogi & Co Ltd

Silence Therapeutics Plc

SK Biopharmaceuticals Co Ltd

Spider Biotech

Stemedica Cell Technologies Inc

Syntiron LLC

TaiRx Inc

Takeda Pharmaceutical Company Ltd

Therakind Ltd

Therashock LLC

TiGenix NV

VBS Pharmaceuticals

Sepsis - Drug Profiles

(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile

3K3A-APC - Drug Profile

7-H9 - Drug Profile

AB-012 - Drug Profile

AB-022 - Drug Profile

AcPepA - Drug Profile

adrecizumab - Drug Profile

ALT-836 - Drug Profile

AM-12 - Drug Profile

AM/AMBP-1 - Drug Profile

Aspidasept - Drug Profile

Atu-111 - Drug Profile

AyuV-25 - Drug Profile

BC-1215 - Drug Profile

BI-113823 - Drug Profile

Biologic to Inhibit PD-L1 for Immunology - Drug Profile

BMS-936559 - Drug Profile

BMS-986189 - Drug Profile

BRL-44408 - Drug Profile

C-23 - Drug Profile

CAR Peptide - Drug Profile

cefiderocol - Drug Profile

ceftaroline fosamil - Drug Profile

Cell Therapy for Sepsis - Drug Profile

Cx-611 - Drug Profile

CYT-107 - Drug Profile

Drug for Sepsis and Septic Shock - Drug Profile

Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile

EC-18 - Drug Profile

Escherichia coli vaccine - Drug Profile

ethinylestradiol - Drug Profile

EV-007156 - Drug Profile

Gamma-PN - Drug Profile

Glyco-23 - Drug Profile

HBN-1 - Drug Profile

HBN-3 - Drug Profile

HBN-4 - Drug Profile

HU-003 - Drug Profile

IFX-1 - Drug Profile

ImmStem - Drug Profile

ImmuneSafe - Drug Profile

IMT-504 - Drug Profile

IR-999 - Drug Profile

Klebsiella pneumoniae vaccine - Drug Profile

L-257 - Drug Profile

L-971 - Drug Profile

LB-100 - Drug Profile

lodelcizumab - Drug Profile

M-33 - Drug Profile

M-6229 - Drug Profile

melatonin - Drug Profile

Metablok - Drug Profile

Monoclonal Antibodies for Sepsis - Drug Profile

Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile

Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile

Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile

Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile

Monoclonal Antibody to Inhibit iNOS for Sepsis - Drug Profile

Monoclonal Antibody to Inhibit Semaphorin 3A for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile

Motrem - Drug Profile

MSP-68 - Drug Profile

NAV-838 - Drug Profile

nivolumab - Drug Profile

NOXD-21 - Drug Profile

OPN-305 - Drug Profile

OTP-300 - Drug Profile

OTP-602 - Drug Profile

Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile

physostigmine salicylate - Drug Profile

pneumococcal vaccine - Drug Profile

PNV-1 - Drug Profile

Protein to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile

Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile

R-190 - Drug Profile

RA-101295 - Drug Profile

RBM-005 - Drug Profile

RECCE-327 - Drug Profile

Recombinant Alkaline Phosphatase Replacement for Sepsis - Drug Profile

Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile

Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile

Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile

Recombinant Protein for Inflammation and Bacterial Sepsis - Drug Profile

Recombinant Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile

Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile

Recombinant Protein to Target Von Willebrand Factor Type A1 Domain for Sepsis - Drug Profile

SAN-101 - Drug Profile

SB-056 - Drug Profile

selepressin - Drug Profile

Slit-2N - Drug Profile

Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile

Small Molecule to HDAC6 for Sepsis - Drug Profile

Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile

Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile

Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile

Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile

Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile

Small Molecules to Inhibit Sialidase for Bacterial Sepsis - Drug Profile

SP-14 - Drug Profile

SP-9 - Drug Profile

Staphylococcus aureus (multivalent) vaccine - Drug Profile

Stem Cell Therapy for Autoimmune Diseases - Drug Profile

Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile

Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile

Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile

Synthetic Peptides for Infectious Disease - Drug Profile

Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile

Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile

TF-0003 - Drug Profile

thrombomodulin alfa - Drug Profile

thymalfasin - Drug Profile

tosatoxumab - Drug Profile

tranexamic acid - Drug Profile

TRX-306 - Drug Profile

vancomycin hydrochloride - Drug Profile

Yersinia pestis vaccine - Drug Profile

Sepsis - Dormant Projects

Sepsis - Discontinued Products

Sepsis - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Sepsis, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Companies, H1 2017 (Contd..3), H1

Number of Products under Development by Universities/Institutes, H1

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Companies, H1 2017 (Contd..3), H1

Products under Development by Companies, H1 2017 (Contd..4), H1

Products under Development by Universities/Institutes, H1

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Sepsis - Pipeline by Adrenomed AG, H1

Sepsis - Pipeline by Altor BioScience Corp, H1

Sepsis - Pipeline by Am-Pharma BV, H1

Sepsis - Pipeline by Arch Biopartners Inc., H1

Sepsis - Pipeline by Aridis Pharmaceuticals LLC, H1

Sepsis - Pipeline by Asahi Kasei Pharma Corp, H1

Sepsis - Pipeline by Astellas Pharma Inc, H1

Sepsis - Pipeline by Batu Biologics Inc, H1

Sepsis - Pipeline by Biomedica Management Corp, H1

Sepsis - Pipeline by Boehringer Ingelheim GmbH, H1

Sepsis - Pipeline by Bristol-Myers Squibb Company, H1

Sepsis - Pipeline by Cell2B Advanced Therapeutics SA, H1

Sepsis - Pipeline by Chiome Bioscience Inc, H1

Sepsis - Pipeline by Cilian AG, H1

Sepsis - Pipeline by Dr. Franz Kohler Chemie GmbH, H1

Sepsis - Pipeline by Endacea Inc, H1

Sepsis - Pipeline by Evec Inc, H1

Sepsis - Pipeline by Ferring International Center SA, H1

Sepsis - Pipeline by Huons Co Ltd, H1

Sepsis - Pipeline by Immune Response BioPharma Inc, H1

Sepsis - Pipeline by Immunethep SA, H1

Sepsis - Pipeline by InflaRx GmbH, H1

Sepsis - Pipeline by Inotrem SA, H1

Sepsis - Pipeline by Integrated BioTherapeutics Inc, H1

Sepsis - Pipeline by Lead Discovery Center GmbH, H1

Sepsis - Pipeline by Leading BioSciences Inc, H1

Sepsis - Pipeline by Lixte Biotechnology Holdings Inc, H1

Sepsis - Pipeline by Merck & Co Inc, H1

Sepsis - Pipeline by Navigen Pharmaceuticals Inc, H1

Sepsis - Pipeline by Nohla Therapeutics Inc, H1

Sepsis - Pipeline by Novartis AG, H1

Sepsis - Pipeline by OncoImmune Inc, H1

Sepsis - Pipeline by Ono Pharmaceutical Co Ltd, H1

Sepsis - Pipeline by Opsona Therapeutics Ltd, H1

Sepsis - Pipeline by Peptinov SAS, H1

Sepsis - Pipeline by ProThera Biologics Inc, H1

Sepsis - Pipeline by Ra Pharmaceuticals Inc, H1

Sepsis - Pipeline by Recce Ltd, H1

Sepsis - Pipeline by Revimmune LLC, H1

Sepsis - Pipeline by Ribomic Inc, H1

Sepsis - Pipeline by SciClone Pharmaceuticals Inc, H1

Sepsis - Pipeline by SetLance srl, H1

Sepsis - Pipeline by Shionogi & Co Ltd, H1

Sepsis - Pipeline by Silence Therapeutics Plc, H1

Sepsis - Pipeline by SK Biopharmaceuticals Co Ltd, H1

Sepsis - Pipeline by Spider Biotech, H1

Sepsis - Pipeline by Stemedica Cell Technologies Inc, H1

Sepsis - Pipeline by Syntiron LLC, H1

Sepsis - Pipeline by TaiRx Inc, H1

Sepsis - Pipeline by Takeda Pharmaceutical Company Ltd, H1

Sepsis - Pipeline by Therakind Ltd, H1

Sepsis - Pipeline by Therashock LLC, H1

Sepsis - Pipeline by TiGenix NV, H1

Sepsis - Pipeline by VBS Pharmaceuticals, H1

Sepsis - Dormant Projects, H1

Sepsis - Dormant Projects, H1 2017 (Contd..1), H1

Sepsis - Dormant Projects, H1 2017 (Contd..2), H1

Sepsis - Dormant Projects, H1 2017 (Contd..3), H1

Sepsis - Discontinued Products, H1

Sepsis - Discontinued Products, H1 2017 (Contd..1), H1

List of Figures:

Number of Products under Development for Sepsis, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Adrenomed AG
  • Altor BioScience Corp
  • Am-Pharma BV
  • Arch Biopartners Inc.
  • Aridis Pharmaceuticals LLC
  • Asahi Kasei Pharma Corp
  • Astellas Pharma Inc
  • Batu Biologics Inc
  • Biomedica Management Corp
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cell2B Advanced Therapeutics SA
  • Chiome Bioscience Inc
  • Cilian AG
  • Dr. Franz Kohler Chemie GmbH
  • Endacea Inc
  • Evec Inc
  • Ferring International Center SA
  • Huons Co Ltd
  • Immune Response BioPharma Inc
  • Immunethep SA
  • InflaRx GmbH
  • Inotrem SA
  • Integrated BioTherapeutics Inc
  • Lead Discovery Center GmbH
  • Leading BioSciences Inc
  • Lixte Biotechnology Holdings Inc
  • Merck & Co Inc
  • Navigen Pharmaceuticals Inc
  • Nohla Therapeutics Inc
  • Novartis AG
  • OncoImmune Inc
  • Ono Pharmaceutical Co Ltd
  • Opsona Therapeutics Ltd
  • Peptinov SAS
  • ProThera Biologics Inc
  • Ra Pharmaceuticals Inc
  • Recce Ltd
  • Revimmune LLC
  • Ribomic Inc
  • SciClone Pharmaceuticals Inc
  • SetLance srl
  • Shionogi & Co Ltd
  • Silence Therapeutics Plc
  • SK Biopharmaceuticals Co Ltd
  • Spider Biotech
  • Stemedica Cell Technologies Inc
  • Syntiron LLC
  • TaiRx Inc
  • Takeda Pharmaceutical Company Ltd
  • Therakind Ltd
  • Therashock LLC
  • TiGenix NV
  • VBS Pharmaceuticals
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll